NPP | Jotup

WINNERS ANNOUNCED: UPL CORP LEADS US$1.75M INVESTMENT IN BIOLOGICAL AG-TECH INNOVATORS

Retrieved on:

Tuesday, March 19, 2024

Radicle, AG, Challenge, Farmer, Growth, Pitch, UPL, Protein, NPP

The Challenge sought to identify entrepreneurs advancing natural and biological solutions and saw applications from 237 start-ups.

Key Points:

The Challenge sought to identify entrepreneurs advancing natural and biological solutions and saw applications from 237 start-ups.
Shireen Davies, CEO of SOLASTA Bio, said: "We are delighted to have won The Radicle NPP Challenge by UPL.
Mike Frank, CEO of UPL Corp., said: "We're committed to expanding access to sustainable solutions as a route to shaping healthy, productive, and climate-positive food systems.
In addition to the funding, SOLASTA Bio and Impetus Ag will gain access to UPL Corp and Radicle Growth's expertise and networks to help accelerate their development and growth.

WINNERS ANNOUNCED: UPL CORP LEADS US$1.75M INVESTMENT IN BIOLOGICAL AG-TECH INNOVATORS

Retrieved on:

Tuesday, March 19, 2024

Radicle, AG, Challenge, Farmer, Growth, Pitch, UPL, Protein, NPP

The Challenge sought to identify entrepreneurs advancing natural and biological solutions and saw applications from 237 start-ups.

Key Points:

The Challenge sought to identify entrepreneurs advancing natural and biological solutions and saw applications from 237 start-ups.
Shireen Davies, CEO of SOLASTA Bio, said: "We are delighted to have won The Radicle NPP Challenge by UPL.
Mike Frank, CEO of UPL Corp., said: "We're committed to expanding access to sustainable solutions as a route to shaping healthy, productive, and climate-positive food systems.
In addition to the funding, SOLASTA Bio and Impetus Ag will gain access to UPL Corp and Radicle Growth's expertise and networks to help accelerate their development and growth.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on:

Tuesday, March 12, 2024

Filtration, Vespula, Toxicity, Histamine, EAACI, Immunotherapy, Asthma, Report, Allergy, Skin, Pregnancy, PR, EEC, MITES, RNA, Criterion, History, CMR, Contraindication, HEP, Draft, Guideline, Patient, Ames test, Diagnosis, Dermatitis, Venom, Literature, Trial of the century, Reproduction, Silicon–germanium, SPT, Food allergy, Cosmetics, EECS, Absorption, Marketing, Safety, Data collection, Directive 2001/83/EC, GMP, ID50, Antibody, Documentation, European, Type IV hypersensitivity, Genotoxicity, Applicant (sketch), Aeroallergen, CHMP, PRIME, Immunoglobulin G, Type, Publication, Biology, Pollen, DNA, Environment, Immune system, Toolbox, NLN, AIT, Atopic dermatitis, Fatality, Chapter, Anaphylaxis, Process validation, ICH, Antigen, Rhinitis, Clinical trial, Erythema, Knowledge, Prescription, Human, Network, Medication, Scope, VIT, ICT, EMA, Collection, Macrophage, Outline, Metabolism, Registry, Inflammation, Immunoglobulin E, Nature, European Pharmacopoeia, Food, Risk, Prevalence, Mastocytosis, Observation, Cytokine, NPP, Patient safety, Disease, Finished, Medical device

16

Key Points:

16
Guideline on allergen products development for
immunotherapy and allergy diagnosis in moderate to lowsized study populations

17

Table of contents

18

Executive summary ..................................................................................... 3

19

1.
Specific effects ................................................................................................. 17
14
15

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 2/18

53

12.
Management for allergies may involve avoidance of the allergen, medications to relieve
66

symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.
71
Recommendations are made on the clinical development, potential study designs and safety

72

considerations for allergen products within the scope of the guideline.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 3/18

88

While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

89

there is no such treatment available for type IV allergies.
93
Several guidelines applicable for allergen products are available (see section 3) and provide advice on

94

quality and clinical development according to the current knowledge.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 4/18

127

However, this guideline does not cover the indication of atopic dermatitis or asthma as these

128

conditions will require separate clinical trials (see Section 6).
129
In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

130

DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

131

substantially to the allergen products as discussed above.
1
156

?

Guideline on the clinical development of products for specific immunotherapy for the treatment

157
158

of allergic diseases - CHMP/EWP/18504/2006
?

159
160
161

Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

?

Guideline on process validation for finished products - information and data to be provided in
regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 5/18

162

?

Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

163

4.
In any
199

case, a reduced validation should include all relevant manufacturing process steps that are considered
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 6/18

200

product specific.
290
Diagnostic allergen products (Type I allergy)

291

A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

292

intracutaneous or provocation testing.
298
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 9/18

305
306

7.1.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 11/18

377

8.
Clinical development of products for AIT: Study design,
efficacy and safety
378

In general, the clinical development should be performed according to current guidelines.
In such single trial, the suitability as a test allergen as well as the
376

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 12/18

415

dose finding for the therapeutic allergen could be investigated.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 13/18

454
455

8.2.1.
493
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 15/18

527

In general, sensitivity and specificity of the product should be determined.
540
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 16/18

561

10.2.
Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024
Page 17/18

595

4.
Allergol Immunopathol, 1989;
602

17(2):53-65

603

Guideline on allergen products development for immunotherapy and allergy diagnosis
in moderate to low-sized study populations
EMA/CHMP/72790/2024

Page 18/18

Westinghouse, Slovenia’s Chamber of Commerce & Industry Host Supplier Event for AP1000® Reactor and AP300™ Small Modular Reactor Deployment

Retrieved on:

Friday, March 8, 2024

Westinghouse Electric Company and the Chamber of Commerce and Industry of Slovenia recently welcomed more than 40 vendors to a Supplier Symposium in Krško.

Key Points:

Westinghouse Electric Company and the Chamber of Commerce and Industry of Slovenia recently welcomed more than 40 vendors to a Supplier Symposium in Krško.
The event builds upon the decades long partnership between Westinghouse and the Slovenian nuclear industry to discuss new opportunities for AP1000® reactor and AP300™ small modular reactor projects in country and globally.
View the full release here: https://www.businesswire.com/news/home/20240308790852/en/
Elias Gedeon, Senior Vice President of Westinghouse Energy Systems Commercial Operations, spoke this week at the Slovenia Supplier Symposium.
The AP300 small modular reactor is the only SMR based on an advanced, large Generation III+ reactor already in operation globally.

'THE RADICLE NPP CHALLENGE BY UPL' REVEALS FINALISTS COMPETING FOR US$1.75M INVESTMENT

Retrieved on:

Wednesday, February 14, 2024

Carbon, Soil, Fungus, Challenge, Growth, Pitch, Nature, Antibody, Health, Bacteria, Crop protection, NPP, UPL, Agriculture, RNA interference, The Challenge, Radicle

The finalists competing for the US$1.75M investment at the Pitch Day Event on March 18th include IBI-Ag, Impetus Agriculture, SOLASTA Bio, and Trillium Ag.

Key Points:

The finalists competing for the US$1.75M investment at the Pitch Day Event on March 18th include IBI-Ag, Impetus Agriculture, SOLASTA Bio, and Trillium Ag.
The four finalists competing for investment are:
IBI-Ag: IBI Ag harnesses the power of antibodies to develop bioinsecticides that target pests with precision while minimizing environmental impact.
A US $1 million investment will be made in The Challenge winner and a US $750,000 investment in the second-place winner to accelerate their growth.
The NPP Radicle Challenge marks the second competition led by UPL in collaboration with Radicle Growth, with a total of US $1.25M invested in two companies in the 2022 'UPL Radicle Carbon & Soil Challenge'.

'THE RADICLE NPP CHALLENGE BY UPL' REVEALS FINALISTS COMPETING FOR US$1.75M INVESTMENT

Retrieved on:

Wednesday, February 14, 2024

Carbon, Soil, Fungus, Challenge, Growth, Pitch, Nature, Antibody, Health, Bacteria, Crop protection, NPP, UPL, Agriculture, RNA interference, The Challenge, Radicle

The finalists competing for the US$1.75M investment at the Pitch Day Event on March 18th include IBI-Ag, Impetus Agriculture, SOLASTA Bio, and Trillium Ag.

Key Points:

The finalists competing for the US$1.75M investment at the Pitch Day Event on March 18th include IBI-Ag, Impetus Agriculture, SOLASTA Bio, and Trillium Ag.
The four finalists competing for investment are:
IBI-Ag: IBI Ag harnesses the power of antibodies to develop bioinsecticides that target pests with precision while minimizing environmental impact.
A US $1 million investment will be made in The Challenge winner and a US $750,000 investment in the second-place winner to accelerate their growth.
The NPP Radicle Challenge marks the second competition led by UPL in collaboration with Radicle Growth, with a total of US $1.25M invested in two companies in the 2022 'UPL Radicle Carbon & Soil Challenge'.

NASA Postdoctoral Program seeks early career and senior scientists for prestigious fellowships at its locations across the U.S.

Retrieved on:

Thursday, January 11, 2024

NASA invites both early-career and senior scientists to explore fellowship opportunities in its postdoctoral program and share in NASA's mission to develop advancements in science, technology, aeronautics and space exploration.

Key Points:

NASA invites both early-career and senior scientists to explore fellowship opportunities in its postdoctoral program and share in NASA's mission to develop advancements in science, technology, aeronautics and space exploration.
Learn more or apply for fellowships in the NASA Postdoctoral Program (NPP).
Scientists who have received their doctorates more than five years previously may apply as a senior fellow.
Stipend rates for these NASA postdoctoral fellows currently start at $70,000 per year.

Axtria Releases Annual Alignment Design and Refinement Benchmarking Study for the Life Sciences Industry

Retrieved on:

Thursday, December 7, 2023

Growth, Workload, Refinement, NPP, Organization, Lens, Alignment, General store

BERKELEY HEIGHTS, N.J., Dec. 7, 2023 /PRNewswire/ -- Axtria Inc., a global leader in award-winning cloud software and data analytics in the life sciences industry, released findings from its annual alignment design and refinement benchmarking study for life sciences organizations.

Key Points:

BERKELEY HEIGHTS, N.J., Dec. 7, 2023 /PRNewswire/ -- Axtria Inc., a global leader in award-winning cloud software and data analytics in the life sciences industry, released findings from its annual alignment design and refinement benchmarking study for life sciences organizations.
The impact of inefficient territory alignment is significant," said Asheesh Sharma, Head of Axtria's Commercial Excellence Practice.
"The right territory design ensures a fair distribution of high-potential targets and maximizes sales opportunities even with a leaner sales force.
The Alignment Design and Refinement Benchmarking Study is now available for demonstration and discussion.

UPL INAUGURATES GLOBAL NPP RESEARCH CENTER, ADVANCING INNOVATION IN SUSTAINABLE AGRICULTURE

Retrieved on:

Thursday, November 16, 2023

Global Nature Fund, Heat, UPL, Open, Disease, LSE, Ecosystem, Health, BSE, NPP, Seaweed, Nature, Soil, NSE, Practice of law, Renewable energy

UPL launches the Global Natural Plant Production (NPP) Research Center in Ramos Arizpe, Mexico

Key Points:

UPL launches the Global Natural Plant Production (NPP) Research Center in Ramos Arizpe, Mexico
LONDON, Nov. 16, 2023 /PRNewswire/ -- UPL Ltd. (NSE: UPL) (BSE: 512070) (LSE: UPLL) ('UPL') a global provider of sustainable agricultural solutions, announces the opening of its Global NPP Research Center in Ramos Arizpe, Mexico.
The Global NPP Research Center, a state-of-the-art facility will advance natural solutions through scientific and applied excellence.
Mike Frank, CEO of UPL Corporation Ltd., said: "We are so proud to inaugurate the Global NPP Research Center today, this significant investment will continue to add value for growers and strengthen our focus on differentiated and sustainable solutions.
Jai Shroff, Group UPL CEO & Chairman, said: "The NPP Research Center reflects UPL's mission to Reimaging Sustainability and our OpenAg commitment to building an ecosystem of connectivity and collaboration.

UPL INAUGURATES GLOBAL NPP RESEARCH CENTER, ADVANCING INNOVATION IN SUSTAINABLE AGRICULTURE

Retrieved on:

Thursday, November 16, 2023

Global Nature Fund, Heat, UPL, Open, Disease, LSE, Ecosystem, Health, BSE, NPP, Seaweed, Nature, Soil, NSE, Practice of law, Renewable energy

UPL launches the Global Natural Plant Production (NPP) Research Center in Ramos Arizpe, Mexico

Key Points:

UPL launches the Global Natural Plant Production (NPP) Research Center in Ramos Arizpe, Mexico
LONDON, Nov. 16, 2023 /PRNewswire/ -- UPL Ltd. (NSE: UPL) (BSE: 512070) (LSE: UPLL) ('UPL') a global provider of sustainable agricultural solutions, announces the opening of its Global NPP Research Center in Ramos Arizpe, Mexico.
The Global NPP Research Center, a state-of-the-art facility will advance natural solutions through scientific and applied excellence.
Mike Frank, CEO of UPL Corporation Ltd., said: "We are so proud to inaugurate the Global NPP Research Center today, this significant investment will continue to add value for growers and strengthen our focus on differentiated and sustainable solutions.
Jai Shroff, Group UPL CEO & Chairman, said: "The NPP Research Center reflects UPL's mission to Reimaging Sustainability and our OpenAg commitment to building an ecosystem of connectivity and collaboration.